{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:02:19Z","timestamp":1791259339306,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shire, Lexington, MA, USA"},{"name":"Shire, Zug, Switzerland"},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-105-2628-B-195-001-MY3, MOST-105-2314-B-195-013, MOST-102-2314-B-195-017-MY3, MOST-104-2314-B-195-019, MOST-102-2314-B-195-006"],"award-info":[{"award-number":["MOST-105-2628-B-195-001-MY3, MOST-105-2314-B-195-013, MOST-102-2314-B-195-017-MY3, MOST-104-2314-B-195-019, MOST-102-2314-B-195-006"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004861","name":"Mackay Memorial Hospital","doi-asserted-by":"publisher","award":["MMH-103-092, MMH-101-111, MMH-I-S-600"],"award-info":[{"award-number":["MMH-103-092, MMH-101-111, MMH-I-S-600"]}],"id":[{"id":"10.13039\/501100004861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0827-1","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T07:20:06Z","timestamp":1528096806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)"],"prefix":"10.1186","volume":"13","author":[{"given":"Hsiang-Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Kuang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shio Jean","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao Chin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuu-Jen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuan-Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"key":"827_CR1","first-page":"3421","volume-title":"The metabolic and molecular bases of inherited disease. 8th edn","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al., editors. The metabolic and molecular bases of inherited disease. 8th edn. New York: McGraw-Hill; 2001. p. 3421\u201352."},{"key":"827_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA"},{"key":"827_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","volume":"28","author":"F Baehner","year":"2005","unstructured":"Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28:1011\u20137.","journal-title":"J Inherit Metab Dis"},{"key":"827_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/ajmg.a.32781","volume":"149A","author":"HY Lin","year":"2009","unstructured":"Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A. 2009;149A:960\u20134.","journal-title":"Am J Med Genet A"},{"key":"827_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/GIM.0b013e3181f6e74d","volume":"12","author":"NJ Mendelsohn","year":"2010","unstructured":"Mendelsohn NJ, Harmatz P, Bodamer O, Burton BK, Giugliani R, Jones SA, et al. Importance of surgical history in diagnosing mucopolysaccharidosis type II (hunter syndrome): data from the hunter outcome survey. Genet Med. 2010;12:816\u201322.","journal-title":"Genet Med"},{"key":"827_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","volume":"10","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J, et al. Initial report from the hunter outcome survey. Genet Med. 2008;10:508\u201316.","journal-title":"Genet Med."},{"key":"827_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1750-1172-6-72","volume":"6","author":"M Scarpa","year":"2011","unstructured":"Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72.","journal-title":"Orphanet J Rare Dis."},{"key":"827_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1590\/S1415-47572014000300003","volume":"37","author":"R Giugliani","year":"2014","unstructured":"Giugliani R, Villarreal ML, Valdez CA, Hawilou AM, Guelbert N, Garzon LN, et al. Guidelines for diagnosis and treatment of hunter syndrome for clinicians in Latin America. Genet Mol Biol. 2014;37:315\u201329.","journal-title":"Genet Mol Biol"},{"key":"827_CR9","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/adc.57.11.828","volume":"57","author":"ID Young","year":"1982","unstructured":"Young ID, Harper PS. Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch Dis Child. 1982;57:828\u201336.","journal-title":"Arch Dis Child"},{"key":"827_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","volume":"25","author":"ID Young","year":"1983","unstructured":"Young ID, Harper PS. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983;25:481\u20139.","journal-title":"Dev Med Child Neurol"},{"key":"827_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1651-2227.2007.00212.x","volume":"96","author":"IV Schwartz","year":"2007","unstructured":"Schwartz IV, Ribeiro MG, Mota JG, Toralles MB, Correia P, Horovitz D, et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl. 2007;96:63\u201370.","journal-title":"Acta Paediatr Suppl"},{"key":"827_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"SA Jones","year":"2009","unstructured":"Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II \u2013 a historical review based on data from the hunter outcome survey (HOS). J Inherit Metab Dis. 2009;32:534\u201343.","journal-title":"J Inherit Metab Dis"},{"key":"827_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167:267\u201377.","journal-title":"Eur J Pediatr"},{"key":"827_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (hunter syndrome). Genet Med. 2006;8:465\u201373.","journal-title":"Genet Med."},{"key":"827_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of hunter syndrome. Genet Med. 2011;13:95\u2013101.","journal-title":"Genet Med."},{"key":"827_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Giugliani R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, et al. Idursulfase treatment of hunter syndrome in children younger than 6 years: results from the hunter outcome survey. Genet Med. 2011;13:102\u20139.","journal-title":"Genet Med."},{"issue":"Suppl 1","key":"827_CR17","first-page":"S13","volume":"44","author":"M del Toro-Riera","year":"2007","unstructured":"del Toro-Riera M. Follow-up of patients with Hunter syndrome: the Hunter Outcome Survey (HOS) registry. Rev Neurol. 2007;44(Suppl 1):S13\u20137.","journal-title":"Rev Neurol"},{"key":"827_CR18","doi-asserted-by":"crossref","unstructured":"del Toro-Riera M. World-wide experience in the treatment of mucopolysaccharidosis type II: the hunter outcome survey (HOS) registry. Rev Neurol 2008;47:S3\u2013S7.","DOI":"10.33588\/rn.47S02.2008580"},{"key":"827_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ejmg.2010.07.013","volume":"53","author":"C Alcalde-Martin","year":"2010","unstructured":"Alcalde-Martin C, Muro-Tudelilla JM, Cancho-Candela R, Gutierrez-Solana LG, Pintos-Morell G, Marti-Herrero M, et al. First experience of enzyme replacement therapy with idursulfase in Spanish patients with hunter syndrome under 5 years of age: case observations from the hunter outcome survey (HOS). Eur J Med Genet. 2010;53:371\u20137.","journal-title":"Eur J Med Genet"},{"key":"827_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ymgme.2010.06.011","volume":"101","author":"BK Burton","year":"2010","unstructured":"Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II \u2013 data from the hunter outcome survey. Mol Genet Metab. 2010;101:123\u20139.","journal-title":"Mol Genet Metab"},{"key":"827_CR21","first-page":"2","volume":"e16","author":"B Link","year":"2010","unstructured":"Link B, de Camargo Pinto LL, Giugliani R, Wraith JE, Guffon N, Eich E, et al. Orthopedic manifestations in patients with mucopolysaccharidosis type II (hunter syndrome) enrolled in the hunter outcome survey. Orthop Rev (Pavia). 2010;e16:2.","journal-title":"Orthop Rev (Pavia)"},{"key":"827_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","volume":"103","author":"BK Burton","year":"2011","unstructured":"Burton BK, Whiteman DA. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the hunter outcome survey (HOS). Mol Genet Metab. 2011;103:113\u201320.","journal-title":"Mol Genet Metab"},{"key":"827_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jpeds.2011.01.054","volume":"159","author":"C Kampmann","year":"2011","unstructured":"Kampmann C, Beck M, Morin I, Loehr JP. Prevalence and characterization of cardiac involvement in hunter syndrome. J Pediatr. 2011;159:327\u201331. e2","journal-title":"J Pediatr"},{"key":"827_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10545-011-9378-5","volume":"35","author":"A Keilmann","year":"2012","unstructured":"Keilmann A, Nakarat T, Bruce IA, Molter D, Malm G. Hearing loss in patients with mucopolysaccharidosis II: data from HOS \u2013 the hunter outcome survey. J Inherit Metab Dis. 2012;35:343\u201353.","journal-title":"J Inherit Metab Dis"},{"key":"827_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00431-013-1967-x","volume":"172","author":"GM Cohn","year":"2013","unstructured":"Cohn GM, Morin I, Whiteman DA. Development of a mnemonic screening tool for identifying subjects with hunter syndrome. Eur J Pediatr. 2013;172:965\u201370.","journal-title":"Eur J Pediatr"},{"key":"827_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ymgme.2013.03.001","volume":"109","author":"SA Jones","year":"2013","unstructured":"Jones SA, Parini R, Harmatz P, Giugliani R, Fang J, Mendelsohn NJ. The effect of idursulfase on growth in patients with hunter syndrome: data from the hunter outcome survey (HOS). Mol Genet Metab. 2013;109:41\u20138.","journal-title":"Mol Genet Metab"},{"key":"827_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ymgme.2016.01.009","volume":"117","author":"R Parini","year":"2016","unstructured":"Parini R, Jones SA, Harmatz PR, Giugliani R, Mendelsohn NJ. The natural history of growth in patients with hunter syndrome: data from the hunter outcome survey (HOS). Mol Genet Metab. 2016;117:438\u201346.","journal-title":"Mol Genet Metab"},{"key":"827_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ymgmr.2017.02.004","volume":"11","author":"O Bodamer","year":"2017","unstructured":"Bodamer O, Scarpa M, Hung C, Pulles T, Giugliani R. Birth weight in patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS). Mol Genet Metab Rep. 2017;11:62\u20134.","journal-title":"Mol Genet Metab Rep"},{"key":"827_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-017-0635-z","volume":"12","author":"J Muenzer","year":"2017","unstructured":"Muenzer J, Jones SA, Tylki-Szymanska A, Harmatz P, Mendelsohn NJ, Guffon N, et al. Ten years of the hunter outcome survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2017;12:82.","journal-title":"Orphanet J Rare Dis."},{"key":"827_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13023-017-0712-3","volume":"12","author":"J Muenzer","year":"2017","unstructured":"Muenzer J, Giugliani R, Scarpa M, Tylki-Szymanska A, Jego V, Beck M. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS). Orphanet J Rare Dis. 2017;12:161.","journal-title":"Orphanet J Rare Dis"},{"key":"827_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","volume":"40","author":"BK Burton","year":"2017","unstructured":"Burton BK, Jego V, Mikl J, Jones SA. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS). J Inherit Metab Dis. 2017;40:867\u20134.","journal-title":"J Inherit Metab Dis"},{"key":"827_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ajmg.a.38551","volume":"176","author":"C Ficicioglu","year":"2017","unstructured":"Ficicioglu C, Giugliani R, Harmatz P, Mendelsohn NJ, Jego V, Parini R. Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: data from the hunter outcome survey (HOS). Am J Med Genet A. 2017;176:301\u201310.","journal-title":"Am J Med Genet A"},{"key":"827_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ymgme.2014.02.009","volume":"111","author":"SM Lin","year":"2014","unstructured":"Lin SM, Lin HY, Chuang CK, Lin SP, Chen MR. Cardiovascular abnormalities in Taiwanese patients with mucopolysaccharidosis. Mol Genet Metab. 2014;111:493\u20138.","journal-title":"Mol Genet Metab"},{"key":"827_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ppul.22774","volume":"49","author":"SP Lin","year":"2014","unstructured":"Lin SP, Shih SC, Chuang CK, Lee KS, Chen MR, Niu DM, et al. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses \u2013 changes with age and treatment. Pediatr Pulmonol. 2014;49:277\u201384.","journal-title":"Pediatr Pulmonol"},{"key":"827_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-016-0471-6","volume":"11","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chuang CK, Huang YH, Tu RY, Lin FJ, Lin SJ, et al. Causes of death and clinical characteristics of 34 patients with mucopolysaccharidosis II in Taiwan from 1995\u20132012. Orphanet J Rare Dis. 2016;11:85.","journal-title":"Orphanet J Rare Dis."},{"key":"827_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ymgme.2016.02.003","volume":"117","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chuang CK, Chen MR, Lin SM, Hung CL, Chang CY, et al. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI. Mol Genet Metab. 2016;117:431\u20137.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0827-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T19:13:48Z","timestamp":1559589228000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0827-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0827-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,4]]},"assertion":[{"value":"13 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Independent Review Board\/Ethics Committee approval was obtained for all participating centres. HOS is conducted in accordance with Good Pharmacoepidemiological Practices (GPP), Good Research for Comparative Effectiveness principles and the relevant principles of the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines (ICH E6). Each patient, their parents or a legal representative provided signed and dated written informed consent for participation in HOS. All patient information is managed in accordance with national data protection standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Each patient, their parents, or a legal representative provided informed consent for publication of data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Professor Shuan-Pei Lin has received grant support and honoraria for speaking engagements from Shire, BioMarin and Sanofi-Genzyme.Dr. Ju-Li Lin received grants from Shire during the conduct of the study.Dr. Hsiang-Yu Lin has received grant support and honoraria for speaking engagements from Shire, BioMarin and Sanofi-Genzyme.All other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"89"}}